Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialAxel Le Cesne, Ole S. Nielsen, Isabelle Ray‐Coquard et al.|Journal of Clinical Oncology|2005Cited by 421
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular targetJaap Verweij, Ole S. Nielsen, A. van Oosterom et al.|European Journal of Cancer|2003Cited by 403
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupAxel Le Cesne, Jaap Verweij, Ian Judson et al.|Journal of Clinical Oncology|2000Cited by 258
A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study updateA. van Oosterom, G. D. Demetri, Peter Reichardt et al.|Journal of Clinical Oncology|2005Cited by 46